Europe Organoids Market Forecast to 2030

Europe Organoids Market Forecast to 2030 – Regional Analysis – by Organ Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Development of Biology Disease, Pathology of infectious Disease, Regenerative Medicines, Drug Discovery and Personalized Medicine, Drug Toxicity and Efficacy Testing, and Others), Source (Pluripotent Stem Cell and Organ Specific Adult Stem Cell), and Type (Instruments, Consumables, and Services)

Send Enquiry

$2,100$3,500

Description

The Europe organoids market is expected to grow from US$ 842.19 million in 2022 to US$ 4,080.52 million by 2030. It is estimated to grow at a CAGR of 21.8% from 2022 to 2030.

Growing Adoption of Personalized Drugs in Europe Organoids Market

Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years.

The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.

Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcomes.

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

Europe Organoids Market Overview

The Europe organoids market is sub-segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. The regional market growth is associated with the rising demand for tissue engineering and organ transplantation; increasing adoption of organoids for disease modeling, gene mutation, and tumor modeling; and growing research activities on organoids. In addition, factors such as increased funding and public–private investments will likely add more opportunities in the coming years in the region.

Europe Organoids Market Revenue and Forecast to 2030 (US$ Million)

Europe Organoids Market Segmentation

The Europe organoids market is segmented into organ type, type, application, source, and country.

Based on organ type, the Europe organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the Europe organoids market in 2022.

Based on type, the Europe organoids market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the Europe organoids market in 2022.

Based on application, the Europe organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the Europe organoids market in 2022.

Based on source, the Europe organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held a larger share of the Europe organoids market in 2022.

Based on country, the Europe organoids market is segmented into the Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. Germany dominated the Europe organoids market in 2022.

Cellesce, Definigen, Hubrecht Organoid Technology, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe organoids market.

Summary Info

Industry:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

At 21.8% CAGR, the Europe Organoids Market is speculated to be worth US$ 4,080.52 million by 2030, says the research team

According to the research team’ research, the Europe organoids market was valued at US$ 842.19 million in 2022 and is expected to reach US$ 4,080.52 million by 2030, registering a CAGR of 21.8% from 2022 to 2030. Focus on drug discovery activities is the critical factor attributed to the Europe organoids market expansion.

The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated to be 356,282. A recent survey by the Hubrecht Institute states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models.

Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ’s original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study ‘CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,’ published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids’ safety, long-term stability, and functionality.

Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.

On the contrary, issues related to incorporation of organoids into existing workflows hampers the Europe organoids market.

Based on organ type, the Europe organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney and others. The intestine segment held 23.2% share of Europe organoids market in 2022, amassing US$ 195.42 million. It is projected to garner US$ 929.64 million by 2030 to expand at 21.5% CAGR during 2022–2030.

Based on type, the Europe organoids market is segmented into instruments, consumables, and services. The consumables segment held 56.6% share of Europe organoids market in 2022, amassing US$ 476.38 million. It is projected to garner US$ 2,425.74 million by 2030 to expand at 22.6% CAGR during 2022–2030.

Based on application, the Europe organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.4% share of Europe organoids market in 2022, amassing US$ 248.01 million. It is projected to garner US$ 1,257.98 million by 2030 to expand at 22.5% CAGR during 2022–2030.

Based on source, the Europe organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.5% share of Europe organoids market in 2022, amassing US$ 610.21 million. It is projected to garner US$ 3,049.98 million by 2030 to expand at 22.3% CAGR during 2022–2030.

Based on country, the Europe organoids market has been categorized into the Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 20.8% share of Europe organoids market in 2022. It was assessed at US$ 175.38 million in 2022 and is likely to hit US$ 893.57 million by 2030, exhibiting a CAGR of 22.6% during 2022–2030.

Key players operating in the Europe organoids market are Cellesce, Definigen, Hubrecht organoid technology, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, among others.

In Feb 2023, the collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe organoids market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Europe organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Europe Key Insights
2.2 Europe Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Organoids Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
5. Europe Organoids Market – Key Industry Dynamics
5.1 Key Market Drivers:
5.1.1 Increasing Demand for Tumor Modeling and Biobanking
5.1.2 Growing Adoption of Personalized Drugs
5.1.3 Rising Focus on Developing Alternatives for Animal Testing Models
5.2 Key Market Restraints:
5.2.1 Issues Related to Incorporation of Organoids into Existing Workflows
5.2.2 Dearth of Skilled Professionals
5.3 Key Market Opportunities:
5.3.1 Focus on Drug Discovery Activities
5.4 Future Trends:
5.4.1 Combining Organoid with Organ-On-A-Chip
5.5 Impact Analysis:
6. Organoids Market – Europe Market Analysis
6.1 Europe Organoids Market Revenue (US$ Mn), 2022 – 2030
7. Europe Organoids Market – Revenue and Forecast to 2030 – by Organ Type
7.1 Overview
7.2 Europe Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
7.3 Stomach
7.3.1 Overview
7.3.2 Stomach: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Intestine
7.4.1 Overview
7.4.2 Intestine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Liver
7.5.1 Overview
7.5.2 Liver: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Pancreas
7.6.1 Overview
7.6.2 Pancreas: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Lung
7.7.1 Overview
7.7.2 Lung: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Brain
7.8.1 Overview
7.8.2 Brain: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.9 Kidney
7.9.1 Overview
7.9.2 Kidney: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Organoids Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Europe Organoids Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Developmental Biology
8.3.1 Overview
8.3.2 Developmental Biology: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Disease Pathology of Infectious Disease
8.4.1 Overview
8.4.2 Disease Pathology of Infectious Disease: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Regenerative Medicine
8.5.1 Overview
8.5.2 Regenerative Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Drug Toxicity and Efficacy Testing
8.6.1 Overview
8.6.2 Drug Toxicity and Efficacy Testing: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Drug Discovery and Personalized Medicine
8.7.1 Overview
8.7.2 Drug Discovery and Personalized Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Organoids Market – Revenue and Forecast to 2030 – by Source
9.1 Overview
9.2 Europe Organoids Market Revenue Share, by Source 2022 & 2030 (%)
9.3 Pluripotent Stem Cells
9.3.1 Overview
9.3.2 Pluripotent Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Organ-specific Adult Stem Cells
9.4.1 Overview
9.4.2 Organ-specific Adult Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10. Europe Organoids Market – Revenue and Forecast to 2030 – by Type
10.1 Overview
10.2 Europe Organoids Market Revenue Share, by Type 2022 & 2030 (%)
10.3 Instruments
10.3.1 Overview
10.3.2 Instruments: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Consumables
10.4.1 Overview
10.4.2 Consumables: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
11. Europe Organoids Market – Country Analysis
11.1 Europe Organoids Market: Overview
11.1.1 Europe Organoids Market by Country
11.1.1.1 Germany
11.1.1.1.1 Overview
11.1.1.1.2 Germany Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.1.3 Germany Organoids Market, by Organ Type
11.1.1.1.4 Germany Organoids Market, by Application
11.1.1.1.5 Germany Organoids Market, by Source
11.1.1.1.6 Germany Organoids Market, by Type
11.1.1.2 UK
11.1.1.2.1 Overview
11.1.1.2.2 UK Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.2.3 UK Organoids Market, by Organ Type
11.1.1.2.4 UK Organoids Market, by Application
11.1.1.2.5 UK Organoids Market, by Source
11.1.1.2.6 UK Organoids Market, by Type
11.1.1.3 France
11.1.1.3.1 Overview
11.1.1.3.2 France Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.3.3 France Organoids Market, by Organ Type
11.1.1.3.4 France Organoids Market, by Application
11.1.1.3.5 France Organoids Market, by Source
11.1.1.3.6 UK Organoids Market, by Type
11.1.1.4 Italy
11.1.1.4.1 Overview
11.1.1.4.2 Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.4.3 Italy Organoids Market, by Organ Type
11.1.1.4.4 Italy Organoids Market, by Application
11.1.1.4.5 Italy Organoids Market, by Source
11.1.1.4.6 Italy Organoids Market, by Type
11.1.1.5 Spain
11.1.1.5.1 Overview
11.1.1.5.2 Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.5.3 Spain Organoids Market, by Organ Type
11.1.1.5.4 Spain Organoids Market, by Application
11.1.1.5.5 Spain Organoids Market, by Source
11.1.1.5.6 Spain Organoids Market, by Type
11.1.1.6 Rest of Europe
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn)
11.1.1.6.3 Rest of Europe Organoids Market, by Organ Type
11.1.1.6.4 Rest of Europe Organoids Market, by Application
11.1.1.6.5 Rest of Europe Organoids Market, by Source
11.1.1.6.6 Rest of Europe Organoids Market, by Type
12. Pre & Post COVID-19 Impact
12.1 Pre & Post COVID-19 Impact
13. Europe Organoids Market Industry Landscape
13.1 Overview
13.2 Growth Strategies Done by the Companies in the Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Europe Organoids Market, Key Company Profiles
14.1 STEMCELL Technologies Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Cellesce Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Hubrecht Organoid Technology
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Definigen
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Thermo Fisher Scientific Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Merck KGaA
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.7 InSphero
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
15. Appendix
15.1 About Us
15.2 Glossary of Terms

LIST OF TABLES

Table 1. Europe Organoids Market Segmentation
Table 2. Germany Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 3. Germany Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 4. Germany Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 5. Germany Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 6. UK Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 7. UK Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 8. UK Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 9. UK Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 10. France Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 11. France Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 12. France Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 13. UK Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 14. Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 15. Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 16. Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 17. Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 18. Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 19. Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 20. Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 21. Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 22. Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Organ Type
Table 23. Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Application
Table 24. Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Source
Table 25. Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn) – Type
Table 26. Organic Developments Done by Companies
Table 27. Inorganic Developments Done by Companies
Table 28. Glossary of Terms, Europe Organoids Market

LIST OF FIGURES

Figure 1. Europe Organoids Market Segmentation, By Country
Figure 2. Europe – PEST Analysis
Figure 3. Europe Organoids Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Europe Organoids Market Revenue (US$ Mn), 2022 – 2030
Figure 6. Europe Organoids Market Revenue Share, by Organ Type 2022 & 2030 (%)
Figure 7. Stomach: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Intestine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Liver: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Pancreas: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Lung: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Brain: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Kidney: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Europe Organoids Market Revenue Share, by Application 2022 & 2030 (%)
Figure 16. Developmental Biology: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Disease Pathology of Infectious Disease: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Regenerative Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Drug Toxicity and Efficacy Testing: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Drug Discovery and Personalized Medicine: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Others: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Europe Organoids Market Revenue Share, by Source 2022 & 2030 (%)
Figure 23. Pluripotent Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Organ-specific Adult Stem Cells: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Organoids Market Revenue Share, by Type 2022 & 2030 (%)
Figure 26. Instruments: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. Consumables: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Services: Europe Organoids Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. Europe Organoids Market, By Country – Revenue (2022) ($Mn)
Figure 30. Europe Organoids Market, By Key Countries, 2022 And 2030 (%)
Figure 31. Germany Organoids Market Revenue And Forecast to 2030 (US$ Mn)
Figure 32. UK Organoids Market Revenue And Forecast to 2030 (US$ Mn)
Figure 33. France Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Italy Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 35. Spain Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Rest of Europe Organoids Market Revenue and Forecast to 2030 (US$ Mn)
Figure 37. Pre & Post COVID-19 Impact
Figure 38. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies – Europe Organoids Market

o Cellesce
o definigen
o Hubrecht organoid technology
o InSphero
o Merck KGaA
o STEMCELL Technologies Inc
o Thermo Fisher Scientific Inc

Reviews

There are no reviews yet.

Be the first to review “Europe Organoids Market Forecast to 2030”